Strikingly, we found a statistically significant increase in the kynurenine/tryptophan ratio, a robust pharmacodynamic marker of the IDO1/Kynurenine pathway (KP), between pre-treatment and on-treatment plasma samples of sarcoma patients treated with Pembrolizumab. The gene discussed is IDO1; the disease is sarcoma.